Monthly Oncology Tumor Boards: Optimal Multidisciplinary Management of Advanced Esophageal Cancer

October 29, 2021

Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer. Treatment for localized disease requires surgical resection with neoadjuvant and/or adjuvant therapy as indicated, while advanced disease is typically treated with palliative/best supportive care with or without systemic therapy. Optimal treatment for resectable disease requires clinician awareness of current evidence regarding the recurrence and survival rates associated with various combined modality approaches. Decisions regarding treatment for advanced or metastatic esophageal cancer require that clinicians be familiar with existing and new systemic therapies and targeted therapies as well as the most effective and tolerable combination regimens. Clinicians need to regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the importance of multidisciplinary care for patients with esophageal cancer.
  • Describe the optimal treatment approach for patients with various presentations of esophageal cancer.
  • Evaluate current evidence for treating advanced esophageal cancer with targeted therapies.
Additional information

This activity is supported by educational grants from: 

  • AstraZeneca
  • Blueprint Medicines
  • Epizyme Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Sanofi Genzyme

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Illumina, Inc
  • Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. 

This activity is supported by an independent educational grant from Astellas.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
10/29/2021 - 1:30pm EDT
Event ends: 
10/29/2021 - 2:30pm EDT

Samuel J. Klempner, MD
Massachusetts General Hospital Cancer Center

Theodore S. Hong, MD
Massachusetts General Hospital Cancer Center

Lana Schumacher, MD
Massachusetts General Hospital Cancer Center


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Samuel J. Klempner, MD
Astellas Pharma US, Inc.: Honoraria
Bristol-Myers Squibb Company: Honoraria
Daiichi-Sankyo Co.: Consulting Fee
Eli Lilly and Company: Honoraria
Merck & Co., Inc.; Honoraria
Natera Inc.: Consulting Fee
Turning Point Therapeutics: Equity Interest/Stock Options

Theodore S. Hong, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
GlaxoSmithKline: Grant/Research Support
Ipsen: Grant/Research Support
Merck & Co., Inc.: Consulting Fee
Novocure: Consulting Fee
Puma Biotechnology: Grant/Research Support
Taiho Pharmaceuticals Co., Ltd.: Grant/Research Support

Lana Y. Schumacher, MD
Intuitive Surgical, Inc.: Grant/Research Support; Product/Speakers Bureau

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-042-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00048269; Approval #: 210003636

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

This webinar was presented live one time only on Friday, October 29, 2021, from 1:30 – 2:30 PM EDT (UTC -4).
The recorded activity is available here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing